Kyowa Hakko Kirin Co., Limited

Kyowa Hakko Kogyo Co., Ltd.

Kyowa Kirin Co., Ltd.

Japan as Represented by President of National Cancer Center

Kazuyasu Nakamura

Nobuo Hanai

Emi Hosaka

Motoo Yamasaki

Kenya Shitara

Yutaka Kanda

Kazuhisa Uchida

Toyohide Shinkawa

Naoko Yamane

Masamichi Koike

Hideharu Anazawa

Mitsuo Satoh

Kazuya Yamano

Akiko Furuya

Susumu Imabeppu

Rinpei Niwa

Yoshihisa Kuwana

Mamoru Hasegawa

Kazuhiro Masuda

Akiko Shimizu

Hiroshi Ando

Kenji Shibata

Akihiro Iida

Mikiko Sakurada

Yuka Sasaki

Eisuke Mekada

Shingo Miyamoto

Mikito Ito

Masabumi Shibuya

Yoko Kawada

Kiyoshi Takatsu

Ryo Iwamoto

Kumiko Takahashi

Emi Shoji

Yuji Ohki

Tsuguo Kubota

Sayaka Hori

Maiko Hirota

Naoki Shimada

Tomoaki Nakagawa

Atsushi Ochiai

So Ohta

Akira Tanaka

Masayo Suzuki

Mariko Nakano

Shinobu Kawamoto

Akiko Tanaka

Rinpel Niwa

Kazuhisa c/o Head Office Kyowa Kogyo Co Ltd Uchida

Emi c/o Biofrontier Laboratories Kyowa Hakko Kogyo Co Ltd Hosaka

Toyohide c/o Bio Process Research And Development Lab Shinkawa

A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Human CDR-grafted antibody and antibody fragment thereof

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

Antibody composition-producing cell

The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.

Method of modulating the activity of functional immune molecules

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependant cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.

Anti-CD4 antibody

A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

Method for producing recombinant antibody and antibody fragment thereof

Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.

Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor

The present invention relates to a cell and mammal in which GDP-mannose 4,6-dehydratase is knocked-out. The cell and mammal are useful for the production of an antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, such as an antibody useful for treating various diseases. The cell and mammal are also useful for the production of a fragment of the antibody, and a fusion protein having the Fc region of the antibody.

Cells with altered fucosylation and producing antibodies therefrom

Growing community of inventors

Machida, Japan

Kazuyasu Nakamura